This inventor holds 1 USPTO granted patent and 5 published patent applications and 1 EPO patent. Top assignee: Reprise Pharmaceuticals, Inc.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Veit Flockerzi: Innovator in Neurodegenerative Disease Treatment
Introduction
Veit Flockerzi is a notable inventor based in Blieskastel, Germany. He has made significant contributions to the field of neurodegenerative disease treatment through his innovative research and patenting efforts. His work focuses on developing methods to treat or prevent conditions such as Multiple Sclerosis, Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis.
Latest Patents
Flockerzi holds a patent for a method of treating or preventing neurodegeneration. This invention relates to a compound that effectively inhibits the function of the TRPM4 ion channel. The patent outlines the use of such compounds in treating or preventing neurodegenerative diseases. Additionally, it provides a pharmaceutical composition that includes a TRPM4 inhibitory compound. The invention also details in vitro methods for identifying pharmaceutically active compounds useful for treating or preventing neurodegenerative diseases. He has 1 patent to his name.
Career Highlights
Veit Flockerzi is associated with Reprise Pharmaceuticals, Inc., where he continues to advance his research in neurodegenerative diseases. His work is pivotal in the ongoing search for effective treatments for these debilitating conditions.
Collaborations
Flockerzi collaborates with talented individuals in his field, including Manuel Friese and Benjamin Schattling. Their combined expertise contributes to the innovative research being conducted at Reprise Pharmaceuticals.
Conclusion
Veit Flockerzi's contributions to the treatment of neurodegenerative diseases highlight his role as an important inventor in the pharmaceutical industry. His innovative methods and collaborative efforts pave the way for future advancements in this critical area of healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile